Radiopharmaceutical developer Navidea Biopharmaceuticals has proposed a nonbinding sublicensing agreement with Cerveau Technologies for the development and marketing of NAV4694, a beta-amyloid imaging agent being evaluated for the diagnosis of Alzheimer's disease using PET.
Under terms of the agreement, Navidea will sublicense NAV4694 to Cerveau in exchange for licensing fees, milestone payments, and royalties.
Cerveau is a partnership between Toronto-based Enigma Biomedical Group and Sinotau Pharmaceutical Group of Beijing; in 2014, Navidea signed an agreement with Sinotau to develop and market its Lymphoseek agent in China. The sublicensing agreement includes a provision that will halt litigation Sinotau has brought against Navidea if a definitive agreement is executed within 60 days, the company said.
